15
Participants
Start Date
June 17, 2021
Primary Completion Date
May 8, 2023
Study Completion Date
May 8, 2023
BIV201 continuous infusion
BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
University of Pennsylvania, Philadelphia
Mercy Medical Center, Baltimore
Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond
Medical University of South Carolina, Charleston
Mayo Clinic Jacksonville, Jacksonville
University of Miami, Miami
Vanderbilt University Medical Center, Nashville
Indiana University, Indianapolis
Mayo Clinic, Rochester
UCLA, Los Angeles
Lead Sponsor
BioVie Inc.
INDUSTRY